# A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)

> **NCT01717287** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 32 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** Raltegravir Film-coated Tablet
- **DRUG:** Raltegravir Chewable Tablet
- **DRUG:** Other Anti-Retroviral Therapy

## Key facts

- **NCT ID:** NCT01717287
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-16
- **Primary completion:** 2013-12-11
- **Final completion:** 2013-12-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01717287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01717287, "A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01717287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*